SCHEMBL688045

SCHEMBL688045

Cc1ccc(Cn2ccc3oc(=O)[nH]c3c2=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
TP53 P04637 3/20 0.55
POLB P06746 3/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
THRB P10828 2/20 0.43
EPHX2 P34913 1/20 0.42
LMNA P02545 2/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 2/20 0.39
NOS1 P29475 2/20 0.39
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.37
HTT P42858 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL688030 0.88 MAPT (0.40) MAPTTP53POLBMEN1KMT2A
SCHEMBL687578 0.87 MAPT (0.48) MAPTTP53POLBMEN1KMT2A
SCHEMBL687659 0.86 MAPT (0.50) MAPTTP53POLBMEN1KMT2A
SCHEMBL688361 0.86 MAPK14 (0.43) TP53POLBMEN1KMT2ALMNA
SCHEMBL687635 0.85 HDAC3 (0.41) MAPTTP53POLBKMT2AEPHX2
SCHEMBL687779 0.85 MAPT (0.49) MAPTTP53MEN1KMT2ALMNA
SCHEMBL688300 0.84 MAPT (0.52) MAPTTP53POLBMEN1KMT2A
SCHEMBL686730 0.83 KDM4E (0.46) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL686689 0.83 DBH (0.43) MAPTTP53POLBMEN1KMT2A
SCHEMBL688113 0.82 TP53 (0.42) MAPTTP53POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063955-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. 2004-04-01 US claimed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP claimed
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed
US-20040063955-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. 2004-04-01 US disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 MAPT 2314/4885TP53 2186/4885POLB 4218/4885
US-20040063955-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, FN1 MAPT 2566/4885TP53 1640/4885POLB 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.